Tristel (TSTL) CMD 2025 summary

Strategic Direction, Growth Outlook, and Financial Performance

• Focus on infection prevention using proprietary chlorine dioxide chemistry, targeting high-level disinfection of medical devices and critical hospital surfaces.

• Achieved 11% revenue growth to £46.5 million and 23% adjusted profit growth to at least £10.1 million, maintaining a debt-free, cash-generative position.

• Ten-year revenue CAGR is 11.6%, with consistent EBITDA growth and a margin target of at least 25% annually from FY25 to FY30.

• Committed to progressive year-on-year dividend growth and double-digit revenue growth through FY30.

• Strategic priorities include global expansion, deeper market penetration, digital leadership, and leveraging clinical guidelines for adoption.

Geographic Expansion and Market Penetration

• 63% of revenues are generated outside the UK, with 18 subsidiaries and operations in 35 countries.

• Recent direct market entries in Spain, Austria, and India, with ongoing investment in Latin America and plans for Japan.

• North America is identified as the largest near-term growth opportunity, with Middle East revenues having tripled recently.

• Significant growth potential remains in underpenetrated markets, aiming to replicate UK success globally.

• Increased investment in commercially focused headcount to drive international market share.

U.S. Market, Product Innovation, and Operational Investments

• Secured FDA approval for ophthalmology products, launching with a mixed direct and distributor sales model.

• Partnership with Parker Laboratories for ultrasound products, earning a 24% royalty in a market of 50 million procedures.

• Early U.S. adoption is driving word-of-mouth growth, with cohabitation alongside legacy systems before full transition.

• Ongoing investment in evidence generation, regulatory submissions, and KOL partnerships to accelerate adoption.

• New recurring revenue streams anticipated from digital platform premium tiers.